An interventional study of auto-crossed-linked hyaluronic acid gel in Retained Products of Conception, sponsored by Fu Xing Hospital, Capital Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Fu Xing Hospital, Capital Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Gynatresia by Fu Xing Hospital, Capital Medical University — 2 open to participants now, 2 under way, none of them phase 3. Gynatresia · Fu Xing Hospital, Capital Medical University.
Among the 10 studies in Gynatresia by Fu Xing Hospital, Capital Medical University, this one is the only one that started in 2022, is one of 7 with no phase, and was the 9th registered.
99 studies on the registry are indexed under Gynatresia; 22 are open to participants now.
Browse Gynatresia studies →2 of the 10 studies in Gynatresia by Fu Xing Hospital, Capital Medical University are open now, in 1 country. Recruiting first, the newest first:
Fu Xing Hospital, Capital Medical University · Sites in China
Ages 20–40 · Women only
By country, each count listing its studies:
Of the 17 Gynatresia studies recruiting now, 1 (6%) sets no upper age limit and 16 (94%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is below the median of 100 across 87 interventional studies indexed under Gynatresia.
Median enrollment 180 across the 9 interventional studies, 600 across the 1 observational. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fu Xing Hospital, Capital Medical University is the lead sponsor of 17 studies on the registry; 5 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Gynatresia by Fu Xing Hospital, Capital Medical University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Retained product of conception (RPOC) is defined by abnormal trophoblastic persistence or retained placenta inside the uterus cavity after a pregnancy independently of the outcome. Untreated RPOC can compromise future fertility. RPOC are generally treated surgically, either by repeated evacuation or by hysteroscopy, which exposes the uterus to additional potential trauma.The combination of trauma to the gravid uterine cavity, hypoestrogenic state at the time of the operation or immediately afterward and local infection is considered to be the pathogenic mechanism of intrauterine adhesions (IUA) , manifested clinically by menstrual abnormalities, infertility and recurrent pregnancy loss.To investigate the efficacy of auto-cross linked hyaluronic acid gel in the prevention of adhesion reformation after hysteroscopic resection of retained products of conception.
After the completion of hysteroscopic resection of retained products of conception, patients will be randomized to one of the two groups by computer-generated numbers: [1] infusing auto-cross linked hyaluronic acid gel into intrauterine cavity in the experimental group; [2] no auto-cross linked hyaluronic acid gel into intrauterine cavity in the control group. Second and third look outpatient hysteroscopy will be performed 4 and 8 weeks after the initial surgery. The patients will be followed up about menstrual pattern at 3 months after the surgery.The patients will be followed up about pregancy outcome at 12 months after the surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
no auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
Other: auto-crossed-linked hyaluronic acid gel
infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
Adhesion reformation rate at third-look hysteroscopy
Time frame: A third-look hysteroscopy will be carried out 8 weeks after the initial operation.Findings are graded according to the American Fertility Society classification.
Adhesion score at third-look hysteroscopy
Time frame: A third-look hysteroscopy will be carried out 8 weeks after the initial operation.Findings are graded according to the American Fertility Society classification.
Concentration of the menstrual pattern
Time frame: at 3 months after the initial surgery
Pregnancy rate
Time frame: at 12-month after the initial surgery
Rate of complications
Time frame: up to 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2022 (actual). Primary completion is estimated for Apr 2025, 36 months after the start.
Of 46 interventional studies with no phase under Gynatresia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 64. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fu Xing Hospital, Capital Medical University